MINERALYS THERAPEUTICS INC
MLYSNASDAQTrading Snapshot
- Day Range
- $24.13 – $24.80
- 52-Week Range
- $22.30 – $47.65
- Volume
- $2.55B
- Avg Volume
- $2.99B
- Shares Outstanding
- 88.2M
- Next Earnings
- Nov 27, 2026
Fundamentals Snapshot
- Annual Revenue
- $186M
- Last Q Revenue
- $49M
- P/E Ratio
- -6.0
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-4.13
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +61.2%
Why Investors Own MLYS
- ✓High-growth profile — revenue up +24.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 25% gross margin and 11% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
MINERALYS THERAPEUTICS INC
MLYS
StockOtter · stockotter.spaceAbout MINERALYS THERAPEUTICS INC
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
RADNOR, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in
Mineralys Therapeutics (NASDAQ:MLYS) Director Brian Taylor Slingsby Sells 104,320 Shares of Company Stock
Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) Director Brian Slingsby sold 104,320 shares of the business's stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price o
Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
RADNOR, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in
Mineralys Therapeutics' Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026
RADNOR, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in
Mineralys Therapeutics (NASDAQ:MLYS) Insider Eric Warren Sells 7,438 Shares
Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) insider Eric Warren sold 7,438 shares of the stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $28.12, for a tota
Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Director Sells $85,740.00 in Stock
Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) Director Daphne Karydas sold 3,000 shares of the stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $28.58, for a